AzTrials
AzTrials

Influence of 8 Months of Increased Physical Activity Workload on Osteoprotegerin and Endocan LevelsNCT02097199

IPHAAB-study Influence of Physical Activity on Atherosclerosis Biomarkers

An observational study of Influence of 8 Months of Increased Physical Activity Workload on Osteoprotegerin and Endocan Levels, run by Medical University of Vienna at 1 site in Austria.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study investigates the influence of an increased physical activity and sports workload in formerly nonsporting healthy individuals on current promising biomarkers of atherosclerosis research. Read more about this study

Who is it for?
Ages 30 to 65 yearsHealthy volunteers can take part
What is being tested?
Increased sports workload
How many people
98 participants
Where
1 siteAustria
Study dates
Aug 2014to Dec 2015
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 30 to 65 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: The study population will consist of about 55 female and 55 male individuals aged 30-65 years with mostly sedentary work (>6 hours/day) doing no or less physical activity (<30 minutes quick walking/day).

Who may be able to join

  • Age 30-65 years
  • less than 30 minutes of quick walking/day
  • Physical ability to perform sports and bicycle stress tests

Who cannot join

  • Age <30 or >65 years
  • Pregnancy
  • weight >130 kg
  • untreated/uncontrolled hypertension

Trial locations and contacts

1 site in 1 country.

Austria1 site
  • Medical University of Vienna

    Vienna, State of Vienna, 1090

Other trials in Austria

About this study

Official title: Influence of Physical Activity on Promising Atherosclerosis Biomarkers

This study investigates the influence of an increased physical activity and sports workload in formerly nonsporting healthy individuals on current promising biomarkers of atherosclerosis research.

Read the detailed description

According to Statistik Austria, cardiovascular disease (CVD) is the most common reason for death in Austria in total population. In 2011, 42,3 % of all deaths were due to CVD (ICD-10 I00-I99). In People aged 45-64 years, CVD is, beyond cancer, the second most common cause of death. According to the "Österreichische Gesundheitsbefragung 2006/7" more than two-thirds of men and three-quarters of women are physically inactive whereby physical inactivity was defined as at least 3x/week of sudatory exercise like cycling, jogging or aerobic.

A very famous study done by Morris et al. in 1953 showed that bus conductors in London (walking job) had half of the coronary heart disease (CHD) mortality compared to bus drivers (sitting job) and therefore initiated the hour of birth of CVD research in connection to physical (in)activity. Cardiorespiratory fitness might reduce does-dependently all cause cardiovascular mortality by 20-30 % (5-8) and the probability of developing CHD by 30-50 % (9-11).

Recently, CVD-research focuses on the investigation of blood-markers which indicate the presence of atherosclerosis and represent risk for development and genesis of CV events. E.g. inflammatory markers such as IL-6, TNF-alpha, ICAM-1, P-selectin, hsCRP and serum amyloid A are promising markers. Studies have shown that hsCRP levels at baseline predict future CV events. Markers of plaque stability are e.g. myeloperoxidase, metalloproteinase-9 and soluble CD-40 ligand. However, the influence of exercise on these factors has already been investigated.

The main dependent variables will be endocan and osteoprotegerin (OPG): OPG is a member of the TNF-related family and involved in bone metabolism. However, high levels of OPG have been reported in association with cardiovascular outcome (CAD, vascular calcification, advanced atherosclerosis, heart failure...). Serum concentrations were found to correlate with severity of peripheral artery disease, carotic stenosis and myocardial infarction. Furthermore, OPG is was associated with left ventricle and left atrial remodelling in patients with severe aortic stenosis, a disease which is often obverse in elderly patients. Age and gender were shown to predict OPG levels, at least in hemodialysis patients. Several studies have been performed investigating the influence of acute exercise or resistance training on circulating OPG amounts but less is known about the influence of long-term physical exercise.

Endocan (endothelial cell specific molecule 1; ESM-1) is a recombinant proteoglycan which may represent a new marker that correlates with CV risk and surrogate endothelial dysfunction playing a role in endothelium-dependent pathological disorders.

Other variables will be:

  • Progerin: Progerin was originally investigated in course of research in Hutchinson-Gilford-Syndrome, a genetic effect which affects children leading to atherosclerosis. Progerin correlates with the vascular pathology of "normal" aging and is present also in the "normal" population.
  • Myeloid-related protein 8 and 14 (MRP-8/14): MRP-8/14 is a stable heterodimer, formed by Ca++-binding proteins. It has been shown that MRP-8/14 regulates vascular inflammation, is involved in diabetic vascular complications and occurs in CAD. Furthermore, MRP-14 was associated with histopathologic findings and inflammation status in atherosclerotic plaques.
  • Angiopoietin-like protein 2 (angptl2): Angptl2 depends to the family of angiopoietin-like proteins and is involved in angiogenesis. Angptl2 was shown to be 6 times higher in mice with CAD compared to controls. Furthermore, it increases with age but this increase was more pronounced in mice with high cholesterol levels. Angptl2 therefore contributes to the genesis and pathogenesis of atherosclerosis.
  • Cathepsin S and K: Cathepsins are synthesized as inactive proenzymes and get activated by proteolytic processes. Atherosclerotic lesions contain much higher amounts of cathepsin S and K than normal arteries. Furthermore, they seem to play a role in the formation of aneurysms.
  • Cystatin C: Cystatin C is a cysteine protease inhibitor participating in protein catabolism and has been suggested to predict CVD. High serum levels of cystatin c were shown to correlate with early stage atherosclerosis. Cystatin C is an independent predictor for the risk of cardiovascular events.
  • Placental growth factor (PlGF): PlGF, a cysteine-knot protein which is quite homologous to VEGF, was implicated in the Pathophysiology of angiogenesis. PlGF-expression in atherosclerotic lesions was shown to be associated with inflammation and microvascular density suggesting PlGF to play a role in plaque destabilization and clinical manifestation of CAD (32). Anti-PlGF monoclonal antibody therapy in mice lead to a decrease in development of atherosclerosis.

All mentioned markers are of distinctive interest in atherosclerosis research, however, the influence of long-term exercise on them has not been studied yet.

Being tested
Increased sports workload
Keywords
activity, osteoprotegerin, endocan, atherosclerosis, biomarker
Medical subject headings
Motor Activity, Atherosclerosis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Increased sports workloadOther

    At least 150 minutes of moderate or 75 minutes of vigorous exercise per week. The "Recommendations for Adults From the American College of Sports Medicine and the American Heart Association" clearly define physical exercise intensity levels. The present study follows these recommendations. Consequently, moderate physical activity can be reached by e.g. quick walking, slow bicycling, slow swimming...; it is also possible to reach the expected workload by engaging in vigorous exercise (e.g. jogging/running, quick swimming, playing soccer/tennis...). The gain in performance will objectified by performing a bicycle stress test at the beginning and the end of the study.

Study groups in NCT02097199
Study groupRoleWhat they receive
Sports groupThe cohort will consist of about 55 female and 55 male individuals aged 30-65 years with mostly sedentary work (>6 hours/day) doing no or less physical activity (<30 minutes quick walking/day) who want to engage more in physical activity (at least 150 minutes of at least moderate intensity per week). The gain in workload will be objectified and quantified by performing a bicycle stress test at the beginning of the study and after 8 months of physical engagement.
Receives: Other: Increased sports workload

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change from baseline osteoprotegerin and endocan level to osteoprotegerin and endocan levels after 8 months of increased physical activity workload

    Osteoprotegerin and endocan levels will be measured at baseline, every 2 months of training and at the end of the observation after 8 months

    Measured: Baseline, Month 8

Secondary outcomes (1)
  1. Change from baseline Progerin, Myeloid-related peptide 8 and 14, Angiopoietin-like protein 2, Cathepsin S and K, Cystatin C and Placental growth factor level to levels after 8 months of increased physical activity workload

    Progerin, Myeloid-related peptide 8 and 14, Angiopoietin-like protein 2, Cathepsin S and K, Cystatin C and Placental growth levels will be measured at baseline, every 2 months of training and at the end of the observation after 8 months

    Measured: Baseline, Month 8

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 Mar 2014 (estimated)
  2. Study startAug 2014
  3. Primary completionNov 2015
  4. Study completionDec 2015

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Time perspective
Prospective
Enrolment
98 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02097199
Sponsor's protocol ID
1830/2013
Status last verified
Jan 2016
First submitted
24 Mar 2014
Last updated
7 Jan 2016
Results posted
No
Data monitoring committee
Yes

Publications

  • Sponder M, Dangl D, Kampf S, Fritzer-Szekeres M, Strametz-Juranek J. Exercise increases serum endostatin levels in female and male patients with diabetes and controls. Cardiovasc Diabetol. 2014 Jan 6;13:6. doi: 10.1186/1475-2840-13-6.

    PubMed 24393402
  • Sponder M, Sepiol K, Lankisch S, Priglinger M, Kampf S, Litschauer B, Fritzer-Szekeres M, Strametz-Juranek J. Endostatin and physical exercise in young female and male athletes and controls. Int J Sports Med. 2014 Dec;35(13):1138-42. doi: 10.1055/s-0034-1375692. Epub 2014 Jul 10.

    PubMed 25009962
  • Sponder M, Fritzer-Szekeres M, Marculescu R, Litschauer B, Strametz-Juranek J. Physical inactivity increases endostatin and osteopontin in patients with coronary artery disease. Heart Vessels. 2016 Oct;31(10):1603-8. doi: 10.1007/s00380-015-0778-6. Epub 2015 Dec 11.

    PubMed 26661073
  • Lenz M, Schonbauer R, Stojkovic S, Lee J, Gatterer C, Lichtenauer M, Paar V, Emich M, Fritzer-Szekeres M, Strametz-Juranek J, Graf S, Sponder M. RANTES and CD40L under Conditions of Long-Term Physical Exercise: A Potential Link to Adaptive Immunity. Int J Environ Res Public Health. 2022 Jul 16;19(14):8658. doi: 10.3390/ijerph19148658.

    PubMed 35886510
  • Sponder M, Lichtenauer M, Wernly B, Paar V, Hoppe U, Emich M, Fritzer-Szekeres M, Litschauer B, Strametz-Juranek J. Serum heart-type fatty acid-binding protein decreases and soluble isoform of suppression of tumorigenicity 2 increases significantly by long-term physical activity. J Investig Med. 2019 Jun;67(5):833-840. doi: 10.1136/jim-2018-000913. Epub 2018 Dec 27.

    PubMed 30593542
  • Sponder M, Campean IA, Emich M, Fritzer-Szekeres M, Litschauer B, Graf S, Dalos D, Strametz-Juranek J. Long-term physical activity leads to a significant increase in serum sRAGE levels: a sign of decreased AGE-mediated inflammation due to physical activity? Heart Vessels. 2018 Aug;33(8):893-900. doi: 10.1007/s00380-018-1125-5. Epub 2018 Jan 24.

    PubMed 29368166
  • Sponder M, Minichsdorfer C, Campean IA, Emich M, Fritzer-Szekeres M, Litschauer B, Strametz-Juranek J. Long-term endurance training increases serum cathepsin S levels in healthy female subjects. Ir J Med Sci. 2018 Aug;187(3):845-851. doi: 10.1007/s11845-017-1693-x. Epub 2017 Nov 27.

    PubMed 29181829
  • Sponder M, Campean IA, Emich M, Fritzer-Szekeres M, Litschauer B, Bergler-Klein J, Graf S, Strametz-Juranek J. Endurance training significantly increases serum endocan but not osteoprotegerin levels: a prospective observational study. BMC Cardiovasc Disord. 2017 Jan 5;17(1):13. doi: 10.1186/s12872-016-0452-7.

    PubMed 28056805

Questions about this trial

What is this clinical trial studying?

An observational study of Influence of 8 Months of Increased Physical Activity Workload on Osteoprotegerin and Endocan Levels, run by Medical University of Vienna at 1 site in Austria.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 7 Jan 2016. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Austria. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change from baseline osteoprotegerin and endocan level to osteoprotegerin and endocan levels after 8 months of increased physical activity workload (time frame: Baseline, Month 8). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02097199, which also lists 8 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Jan 2016.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in